Maravai LifeSciences Holdings, Inc. Stock News

Marshall Wace LLP trimmed its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 68.8% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 73,964 shares of the companys stock after selling 163,221 shares during the quarter. Marshall Wace LLPs holdings in Maravai LifeSciences were worth $3,087,000 as of its most recent []

Wall Street brokerages predict that Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) will post $0.38 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Maravai LifeSciences earnings, with the highest EPS estimate coming in at $0.43 and the lowest estimate coming in at $0.35. Maravai LifeSciences posted earnings of $0.13 []

Carnegie Capital Asset Management LLC purchased a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 12,580 shares of the companys stock, valued at approximately $617,000. Several other hedge funds also recently modified their []

Goldman Sachs Group Inc. raised its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 5.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 137,028 shares of the companys stock after buying an additional 6,800 shares during the quarter. Goldman Sachs []

Maravai LifeSciences (NASDAQ:MRVI) updated its FY 2021 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $1.480-$1.520 for the period, compared to the Thomson Reuters consensus estimate of $1.390. The company issued revenue guidance of $770 million-$780 million, compared to the consensus revenue estimate of $764.03 million.Maravai LifeSciences also updated its []

Related Stocks: ICLR , TMO , GLOB , HTGC , OMCL , TECH , MRVI , DOCS , MRNA , AVTR , STLD , CPRI , BRK.B , SMG , TKR , PNR , TFX , GM ,

Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) price closed lower on Monday, November 15, dropping -1.73% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

The consensus price target hints at a 40.2% upside potential for Maravai LifeSciences (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni

Maravai LifeSciences (NASDAQ:MRVI) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Saturday, Zacks.com reports. The firm presently has a $41.00 price target on the stock. Zacks Investment Researchs price target points to a potential upside of 9.01% from the companys previous close. According to []

Maravai LifeSciences Holdings, Inc. (MRVI) CEO Carl Hull on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to p

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans t

CNXC, DLTH, NVEE, MRVI, and PFSI have been added to the Zacks Rank #1 (Strong Buy) List on October 8, 2021.

Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics

EyeGene expected to utilize TriLink's CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials EyeGene expected to uti